# GLENMARK share price, delivery % and history — Glenmark Pharmaceuticals Limited

> Delivery percentage for Glenmark Pharmaceuticals Limited (GLENMARK) against its own history, with 6,618 sessions of split-adjusted NSE data from 2000 — plus moving averages, RSI and the 52-week range.

Canonical: https://patternsradar.com/s/GLENMARK

NSE · equity · [Healthcare](https://patternsradar.com/stocks/sector/healthcare.md) · [Pharmaceuticals & Biotechnology](https://patternsradar.com/stocks/industry/pharmaceuticals-biotechnology.md)

## Latest session

- Close: 2,334.7 INR (-4.37% on the day), 2026-09-30
- Delivery: 56.43% of volume taken to demat (20-day average 53.53%)
- Volume: 12.62L shares, turnover ₹294.6Cr
- Relative volume: 2.28× of its own 20-day average

## Technicals

- RSI(14): 43.66
- ATR(14): 67.77
- SMA 50: 2,351.27, SMA 200: 2,198.54
- 52-week range: 1,792.6 – 2,537.6 (-8% from the high)

## Performance

- 1 week -5.67%, 1 month -5.86%, 3 months 6.32%
- 6 months 7.57%, 1 year 15.76%

## Delivery percentage

- Latest: 56.43% (2026-09-30)
- 20-day average: 53.53%
- 1-year average: 47.05%
- Percentile against its own history: 92th
- Range: 4.27% – 80.03% across 1,728 sessions with a reading

Over the last 20 sessions GLENMARK settled 53.5% of its traded quantity, which is above average for an NSE equity. Its one-year average is 47.0%, so recent sessions are running 6.5 points higher than usual. The latest session ranks higher than 92% of the 1,728 sessions on record for it.

[What delivery percentage measures](https://patternsradar.com/learn/delivery-percentage.md). [Scan the whole market on delivery](https://patternsradar.com/scans/delivery.md).

## Fundamentals

- Market cap: 65,891 crore
- P/E (TTM): 36.65 — NULL when trailing earnings are negative or unfiled, never a misleading number
- EPS (TTM): 63.7 INR, split-adjusted to match the price series
- Revenue growth: 23.1% YoY, 6.57% QoQ
- Profit growth: 927.88% YoY, 60.24% QoQ

Compound annual growth, trailing-twelve-month against the same measure N years earlier:

| Window | Revenue | Profit |
| --- | --- | --- |
| 2y | 21.47% | — |
| 3y | 9.22% | 74.31% |
| 4y | 9.99% | 18.94% |
| 5y | 8.93% | 11.95% |
| 6y | 8.85% | 11.8% |
| 7y | 8.5% | 12.24% |

## Quarterly results

Last 8 filed quarters, consolidated basis, in rupees crore as filed.

| Quarter | Revenue | Total expenses | Profit before tax | Net profit | EPS | Net margin |
| --- | --- | --- | --- | --- | --- | --- |
| 2024-09-30 | 3,433.8 | 3,000.6 | 472.6 | 354.5 | 12.55 | 10.32% |
| 2024-12-31 | 3,387.6 | 2,962.4 | 456.3 | 348 | 12.33 | 10.27% |
| 2025-03-31 | 3,256.2 | 2,887.1 | 8 | 4.4 | 0.16 | 0.13% |
| 2025-06-30 | 3,264.4 | 2,872.1 | 95.6 | 47 | 1.66 | 1.44% |
| 2025-09-30 | 6,046.9 | 3,895 | 967.4 | 610.4 | 21.63 | 10.1% |
| 2025-12-31 | 3,900.6 | 3,226.7 | 534 | 403.2 | 14.29 | 10.34% |
| 2026-03-31 | 3,770.6 | 3,198.5 | 387.8 | 301.3 | 10.68 | 7.99% |
| 2026-06-30 | 4,018.5 | 3,440.9 | 643.4 | 482.8 | 17.11 | 12.02% |

A quarterly filing with NSE carries a profit and loss only. There is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure in this dataset. EPS is restated onto the split-adjusted basis the price series uses; every rupee figure is exactly as filed.

## Shareholding

As filed for 2026-06-30:

- Promoter: 46.65%
- Public: 53.35%
- FII: 20.89%, DII: 18.6%
- Promoter shares pledged: 0%

## Recent filings

- 2026-08-31: dividend
- 2026-07-31: results for 2026-06-30 both — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_181350_31072026195216_iXBRL_WEB.html
- 2026-07-16: shareholding for 2026-06-30 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1693887_16072026123852_WEB.xml
- 2026-05-29: results for 2026-03-31 both — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_164387_29052026231208_iXBRL_WEB.html
- 2026-04-15: shareholding for 2026-03-31 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1651479_15042026050854_WEB.xml
- 2026-01-30: results for 2025-12-31 both — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_139419_30012026202310_iXBRL_WEB.html
- 2026-01-13: shareholding for 2025-12-31 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1600063_13012026054249_WEB.xml
- 2025-11-14: results for 2025-09-30 both — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_128444_14112025205140_iXBRL_WEB.html

Dated by the day the company broadcast the filing. 116 events are indexed for this instrument.

## About the instrument

- Listed: 2000-02-10 — latest session 2026-09-30 (6,618 sessions)
- ISIN: INE935A01035
- Series: EQ
- Liquidity rank: #228 by 20-day average turnover — not index membership

Delivery figures come from NSE's daily reports and are unavailable for older sessions. Prices are end-of-day, split- and bonus-adjusted, from the eod2 dataset.

## More in Pharmaceuticals & Biotechnology

- [DIVISLAB](https://patternsradar.com/s/DIVISLAB.md) — Divi's Laboratories Limited (Pharmaceuticals & Biotechnology)
- [LAURUSLABS](https://patternsradar.com/s/LAURUSLABS.md) — Laurus Labs Limited (Pharmaceuticals & Biotechnology)
- [WOCKPHARMA](https://patternsradar.com/s/WOCKPHARMA.md) — Wockhardt Limited (Pharmaceuticals & Biotechnology)
- [SUNPHARMA](https://patternsradar.com/s/SUNPHARMA.md) — Sun Pharmaceutical Industries Limited (Pharmaceuticals & Biotechnology)
- [MOREPENLAB](https://patternsradar.com/s/MOREPENLAB.md) — Morepen Laboratories Limited (Pharmaceuticals & Biotechnology)
- [DRREDDY](https://patternsradar.com/s/DRREDDY.md) — Dr. Reddy's Laboratories Limited (Pharmaceuticals & Biotechnology)
- [SYMBIOTEC](https://patternsradar.com/s/SYMBIOTEC.md) — SYMBIOTEC (Pharmaceuticals & Biotechnology)
- [GLAND](https://patternsradar.com/s/GLAND.md) — Gland Pharma Limited (Pharmaceuticals & Biotechnology)
- [ZYDUSLIFE](https://patternsradar.com/s/ZYDUSLIFE.md) — Zydus Lifesciences Limited (Pharmaceuticals & Biotechnology)
- [TORNTPHARM](https://patternsradar.com/s/TORNTPHARM.md) — Torrent Pharmaceuticals Limited (Pharmaceuticals & Biotechnology)
- [LUPIN](https://patternsradar.com/s/LUPIN.md) — Lupin Limited (Pharmaceuticals & Biotechnology)
- [AHCL](https://patternsradar.com/s/AHCL.md) — Anlon Healthcare Limited (Pharmaceuticals & Biotechnology)

[All Pharmaceuticals & Biotechnology stocks on the NSE](https://patternsradar.com/stocks/industry/pharmaceuticals-biotechnology.md) · [All Healthcare stocks on the NSE](https://patternsradar.com/stocks/sector/healthcare.md)

Charts and the full bar history are on the rendered page: https://patternsradar.com/s/GLENMARK.

---

Price and delivery data from the [eod2](https://github.com/BennyThadikaran/eod2) dataset: National Stock Exchange of India end-of-day files, split- and bonus-adjusted, updated after each close. Not affiliated with or endorsed by NSE. PatternsRadar is a research tool. Nothing here is investment advice or a recommendation to buy or sell anything.